Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:47:34.359Z.
Consensus retrieved: 2026-10-06T14:19:34.943Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:47:34.359Z.
Quote observation: 2026-10-06T15:43:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7cda135bbdc40ab96f6f5c38083b7dd78a9f140dcd8a254691991f8eaa2b9dc4
FORWARD PE RATIO
N/A
Neuphoria Therapeutics Inc.
Market Cap
$18.86M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | $18.86M | N/A |
| NextCure, Inc. (NXTC)vs › | $19.14M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.40M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.64M | N/A |
| P3 Health Partners Inc. (PIII)vs › | $20.00M | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.52M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.19M | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | N/A |
| PAVmed Inc. (PAVM)vs › | $17.11M | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.80M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-06-30
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
